More OncoSil Medical Ltd news
OncoSil Medical LtdASX: OSL

Positive PanCO trial update on resected cohort

Oct 19, 2020 at 10:02 PM EDT · Issued by OncoSil Medical Ltd

Filed with ASX · Oct 19, 2020 at 10:02 PM EDT

On 6ix: 6ix.com/news/positive-panco-trial-update-on-resected-cohort

Oncosil Medical Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

OncoSil Medical Ltd on 6ix

In the deck

  • OncoSil Medical — Shareholder Meeting (October 2020)11 slidesOct 20, 2020

Story so far

  • PanCo Study Interim AnalysisOct 25, 2018

Earlier from OncoSil Medical

  • Receipt of $2.8m R&D Tax Incentive RefundSep 22, 2020
  • Investor UpdateAug 28, 2020
  • OncoSil receives Malaysian regulatory approvalAug 27, 2020
  • Preliminary Final Report - Appendix 4E AnnouncementAug 19, 2020
  • HDE filing submitted in US for Bile Duct Cancer treatmentJul 27, 2020

Later from OncoSil Medical

  • OncoSil achieves first commercial saleOct 21, 2020
  • OncoSil receives Swiss regulatory approvalNov 4, 2020
  • Termination of Mr Daniel Kenny as Chief Executive OfficerDec 1, 2020
  • OncoSil FY21 half yearly reviewJan 18, 2021
  • Appointment of Chief Executive OfficerJan 21, 2021
All OncoSil Medical news releases↗

Follow OncoSil Medical into a list and get an email when it puts out news.

Follow OncoSil Medical
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer